A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE:BMY). With a market cap of over $100 billion and a history dating back to 1887, the big pharma has a lot of muscle to put behind its enormously successful cancer drug Opdivo.
